ResMed versus the street

Tough night on the street for RMD, as the San Diego-based company reported after market in the US and pre-market for the Australian listing.

RMD reported first quarter net profit of US$80.9 million, which is a strong beat on the corresponding period of US$71.3 million (a 14% beat), with revenue up 5% to US$357.7 million from US$339.7 million last year. Earnings-per-share came in at 56 cents – also a strong beat on the 49 cents reported in the corresponding period.

The street estimates, however, were for an earnings-per-share read of 58 cents and revenue read of US$373.3 million. The soft revenue print to street estimates are contributed to increase competition, pricing discounts and some loss of market share in the lucrative masks division. What will also upset the market is the fact flow generators from sleep apnea only saw 5% growth, which produces around 35% of EBIT.

The market has reacted to the news with a -9% drop on the open. This is not surprising on a fundamental basis as the stock was trading at a 22 times price-to-earnings on consensus FY14 numbers. However I see the results as broadly in line with company expectations which have seen expected increased competition.

What is very positive from the numbers is gross profit margin, which is up 230 basis points on the corresponding, to 63.7%, and beat market expectations. The margins were a reaction to the lower AUD increased manufacturing from Singapore and a shift to higher end devices, which is a longer term strategy. These are longer-term positive and if the product mix shifts to high-end devices, RMD will see margin move higher still.

Trade suggestion

The ASX listing is up over 50% for the year and the US listing is up 37%. The momentum in the trade I believe will return, however near term trading will be weak. I suggest holding out of the trade until the interim momentum changes.

I see three to five days of selling before the stock is picked up. The upward trend that began in July last year has not been broken with today’s sell-off and if it holds the line, the reversal post the sell-off should see the stock head back towards $6.

Look to buy the dips on reversal signals; buying dips around 5.20 to $5.35 would be beneficial, with a stop loss at $5.15 and limit of $5.95.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

CFD’s zijn complexe instrumenten en brengen vanwege het hefboomeffect een hoog risico mee van snel oplopende verliezen. 79% van de retailbeleggers lijdt verlies op de handel in CFD’s met deze aanbieder.
Het is belangrijk dat u goed begrijpt hoe CFD's werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
CFD’s zijn complexe instrumenten en brengen vanwege het hefboomeffect een hoog risico mee van snel oplopende verliezen.